Moneycontrol
HomeNewsBusinessReal EstateCOVID-19 impact | Nearly half of co-working space operated by small players may get vacated
Trending Topics

COVID-19 impact | Nearly half of co-working space operated by small players may get vacated

Small operators will not be able to sustain due to their disproportionate exposure to start-ups and SME tenants that do not have the financial muscle to outlive the coronavirus pandemic

June 19, 2020 / 14:39 IST
Story continues below Advertisement

The smaller co-working space operators are expected to find it very difficult to weather the COVID-19 storm and at least half of this stock amounting to 3.2 million quarter feet (msf) will be vacated by their operators within 2020 as these small operators fade away, according to a Knight Frank report.

Approximately 25 percent, that is 6.4 million square feet (msf) of the total 25.45 msf co-working stock in the top eight cities is operated by small players.

Story continues below Advertisement

Low occupancy and increasing cost are expected to make co-working operations unviable for fringe players and would therefore, force smaller players to vacate their low performing offices, according to a report titled: ‘Co-working: Surviving COVID-19’ by Knight Frank India.

“The Indian co-working business, much like other sectors will feel the impact of the COVID-19 pandemic with the fringe players likely to make an exit. This will be a period of shake-out for this segment where we expect larger players with a greater weightage of enterprise tenants to endure,” said Shishir Baijal, Chairman & Managing Director, Knight Frank India.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show